These findings have implications for the treatment of insulin resistance in diabetic patients, concerning the facts that the beneficial effect on insulin sensitivity could be demonstrated under the conditions of established obesity and insulin resistance, and that pioglitazone, i.e. the only TZD approved for clinical use at present, was shown to exert the effect. The gene discussed is INS; the disease is Obesity.